Oculis Holding AG (OCS) stock: key figures, P/E, revenue and dividend
Health Care · Switzerland · ISIN CH1242303498
Oculis Holding AG financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Gross profit | 0.00 USD |
| Operating income | -98.68 m USD |
| EBIT | -119.59 m USD |
| Net income | -119.56 m USD |
| Diluted EPS – continuing operations | -2.56 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
More stocks
- AVIT Ltd (300264.SZ)
- Fujian South Highway Machinery Co. Ltd. A (603280.SS)
- Shaanxi Jinye Science Technology and Education Group Co Ltd (000812.SZ)
- Kunshan Asia Aroma Corp. Ltd. (301220.SZ)
- Agora Inc (API)
- Yonker Environmental Protect (300187.SZ)
- Jaya Sukses Makmur Sentosa Tbk PT (RISE.JK)
- Frontera Energy Corp (FEC.TO)
- Huchems (069260.KS)
- Van de Velde NV (VAN.BR)
- Shanghai Laimu Electronics Co Ltd (603633.SS)
- Suwen Electric Energy Technology Co.Ltd (300982.SZ)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.